Evidence map›Paper›PMID 41267982›Full record

ArticleFrontiers in oncology2025

Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.

Akinao Okamoto, Masahiro Yoshida, Senji Kasahara, Takahide Ara, Kazutaka Ozeki, Takanobu Morishita, Daisuke Ikeda, Minoru Kanaya, Tomohiro Kajiguchi, Yasuhiro Suzuki and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Akinao OkamotoDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
Masahiro YoshidaDepartment of Hematology, Osaka City General Hospital, Osaka, Japan.
Senji KasaharaDepartment of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Takahide AraDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Kazutaka OzekiDepartment of Hematology and Oncology, JA Aichi Konan Kosei Hospital, Konan, Japan.
Takanobu MorishitaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Daisuke IkedaDivision of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
Minoru KanayaBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.
Tomohiro KajiguchiDepartment of Hematology and Oncology, Tosei General Hospital, Seto, Japan.
Yasuhiro SuzukiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Shingo KurahashiDepartment of Hematology and Oncology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Tomohiro HorioDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Yoshiaki MarumoDepartment of Hematology and Oncology, Nagoya City University, Nagoya, Japan.
Tatsuo OyakeDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Shigeki SaitoDepartment of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Hitomi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Shun-Ichi KimuraDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Takahiro NishiyamaDivision of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Kurashiki, Japan.
Junji HiragaDepartment of Hematology, Toyota Kosei Hospital, Toyota, Japan.
Hiroki HosoiDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Yasufumi MasakiDepartment of Hematology and Immunology, Kanazawa Medical University, Kanazawa, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Hideyuki YamamotoDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
Takahiko MiyamaDepartment of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan.
Naoe GotoDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
Chisako IriyamaDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
Keichiro MiharaInternational Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan.
Yoshihiro InamotoDepartment of Blood and Marrow Transplantation and Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan.
Akihiro TomitaDepartment of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although the Omicron variant has been reported to reduce COVID-19 severity in the general population, its impact on patients with hematologic malignancies remains uncertain, and epidemiological investigation is warranted. Methods: We conducted a multicenter retrospective cohort study of 1, 023 patients with hematologic diseases diagnosed with COVID-19 at 22 centers in Japan between January 2020 and January 2023. Outcomes within 60 days after diagnosis including severe and/or prolonged disease, COVID-19-related mortality, and overall survival (OS) were compared between the pre-Omicron and Omicron periods. Multivariable analysis was performed to identify independent adverse prognostic factors. Results: Severe and/or prolonged disease occurred in 27.5% of patients, COVID-19-related mortality was 6.3%, and OS was 91.4%. Compared with the pre-Omicron period, the Omicron period was associated with significantly lower rates of severe/prolonged disease (26.0% vs. 48.0%, Conclusion: In patients with hematologic diseases, the Omicron period was associated with reduced severity and COVID-19-related mortality but no improvement in OS. Older age and prior bendamustine exposure were strongly associated with adverse outcomes, highlighting the need for strict infection prevention and prompt, aggressive COVID-19 management in these high-risk populations.

Indexed as

COVID-19hematologic diseasesimmunocompromised patientsmulticenter studyOmicron variantprognosis

Identifiers

PMID41267982
PMCPMC12626787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.